LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova (LIVN) will provide general business updates through executive leadership fireside chats at four healthcare conferences in November 2026.
The appearances are at UBS on November 9, Wolfe Research on November 10, Stifel on November 11, and Jefferies on November 17. Registered participants can access webcasts through the company website; replays will be available within 24 hours after each live presentation.
LivaNova (LIVN) will host a conference call to discuss its third-quarter 2026 results on November 4, 2026, at 1 p.m. GMT (8 a.m. EST). The company will release results prior to the call.
The live audiocast will be available at www.livanova.com/events, with phone access via +1 833 461 5787 (U.S.) or +1 585 542 9983 (international), using meeting ID 495924914. A replay will be posted in the Investors section of the LivaNova website.
LivaNova (LIVN) will present at two healthcare investor conferences in New York City in September 2026.
The company will join the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, from 11:30 a.m. to 12:05 p.m. EDT, and the Baird 2026 Global Healthcare Conference on Tuesday, Sept. 15, from 11:25 a.m. to 11:55 a.m. EDT. Senior executives, including the CEO, CFO, Chief Strategy and Corporate Development Officer, and Chief Innovation Officer, will participate. Live webcasts and replays will be accessible through the LivaNova events webpage.
LivaNova (Nasdaq: LIVN) reported second-quarter 2026 revenue of $390.6 million, up 10.8% reported and 9.8% on a constant-currency basis versus 2025. Cardiopulmonary revenue rose 11.2% and Neuromodulation 10.1%. U.S. GAAP diluted EPS was $1.93, with adjusted diluted EPS of $1.26. Operating cash flow was $66.6 million and adjusted free cash flow $45.5 million.
The company raised 2026 guidance, now expecting constant-currency revenue growth of 8–9% and adjusted EPS of $4.30–$4.40, while lowering adjusted free cash flow guidance to $140–$160 million to fund strategic investments. LivaNova entered a long-term supply agreement with Thermo Fisher Scientific to increase availability of a critical oxygenator component and reported an €81.8 million ($95.4 million) discrete tax benefit from a favorable Italian tax ruling related to the SNIA environmental liability. The company also highlighted positive data for its PolySync programming algorithm in Obstructive Sleep Apnea and announced several senior leadership appointments.
LivaNova (Nasdaq: LIVN) will host a conference call to discuss its Q2 2026 results on Wednesday, August 5, 2026, at 1 p.m. London time (8 a.m. EDT).
The company will release results before the call, with live audiocast and replay available on its website.
LivaNova (Nasdaq: LIVN) reported new OSPREY substudy data showing its PolySync programming algorithm raised the cumulative apnea-hypopnea index (AHI) response rate to 84.5% in moderate to severe Obstructive Sleep Apnea treated with proximal hypoglossal nerve stimulation (pHGNS).
Reprogramming non-responders with simultaneous-contact stimulation converted most into responders, improved AHI and oxygen desaturation index, and showed no serious treatment-emergent or device-related adverse events. LivaNova plans a PMA supplement for its next-generation, MRI-compatible, rechargeable OSA device in the second half of 2026.
LivaNova (Nasdaq: LIVN) elected Jette Nygaard-Andersen to its Board of Directors following the June 10 Annual General Meeting. She brings more than 25 years of leadership in regulated international businesses, including roles at Coloplast, Entain and Modern Times Group.
Dr. Sharon O’Kane stepped down after a decade on the Board. Committee leadership changes include Brooke Story as Chair of the Nominating and Corporate Governance Committee and Peter Wilver as Chair of the Compensation and Human Capital Management Committee, while William Kozy remains Board Chair.
LivaNova (Nasdaq: LIVN) appointed Anne Liddy as Chief Legal Officer, effective August 31. She will lead the global legal and compliance function and join the Executive Leadership Team.
Liddy brings over 20 years of healthcare and life sciences legal experience, including senior roles at Hologic, Pfizer, and Ropes & Gray.
LivaNova (Nasdaq: LIVN) appointed Stefano Folli as incoming President, Cardiopulmonary, effective June 1, 2026, succeeding Franco Poletti, who retires July 31.
Folli joins the Executive Leadership Team, reporting to the CEO, and will oversee strategic growth of the nearly $800 million Cardiopulmonary business.
LivaNova (Nasdaq: LIVN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami Beach on June 8, 2026, at 8:00 a.m. EDT. A live webcast and replay will be accessible via the LivaNova events webpage.